Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma – a systematic review and meta-analysis

Background: New, complex, and expensive therapies targeting Interleukin-5 (IL-5) to treat severe eosinophilic asthma are emerging. Objective: To assess efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab for treating severe eosinophilic asthma. Design: A systematic revi...

Descripción completa

Detalles Bibliográficos
Autores principales: Henriksen, Daniel P., Bodtger, Uffe, Sidenius, Kirsten, Maltbaek, Niels, Pedersen, Lars, Madsen, Hanne, Andersson, Ehm A., Norgaard, Ole, Madsen, Louise Klokker, Chawes, Bo L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282428/
https://www.ncbi.nlm.nih.gov/pubmed/30533206
http://dx.doi.org/10.1080/20018525.2018.1536097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282428/
https://www.ncbi.nlm.nih.gov/pubmed/30533206
http://dx.doi.org/10.1080/20018525.2018.1536097

Ejemplares similares